Antiviral combination plus standard therapy achieves ‘controlled biological state’ in HBV

LONDON — Therapy combining small interfering RNA, capsid assembly modulator and nucleotide analogue reduced HBsAg levels over 24 weeks compared with standard therapy, according to a presenter at the International Liver Congress.“It’s important that we think about public health and global viruses and liver disease, and hepatitis B is a globally relevant virus,” Kosh Agarwal, MD, from the Institute of Liver Studies at King’s College Hospital in London, told attendees. “I believe the latest estimates suggest that almost 300 million people in the world areRead More